BioCryst Pharmaceuticals, Inc. BCRX

Company Overview

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, and commercialization of oral small-molecule medicines targeting rare diseases. The company operates primarily within the biopharmaceutical and rare disease therapeutics industries, with a strategic emphasis on diseases driven by dysregulated immune and inflammatory pathways. Its business model centers on advancing proprietary compounds from internal research through late-stage development and global commercialization.

The company’s primary revenue drivers are its approved products Orladeyo (berotralstat) for hereditary angioedema (HAE) and Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome (APDS), alongside government-related sales of Rapivab (peramivir) for influenza. BioCryst serves specialist physicians, hospitals, and rare disease patient populations, with a particular focus on immunology and complement-mediated disorders. Founded in 1986, BioCryst originally focused on structure-based drug design and antiviral research, later evolving into a commercial-stage rare disease company through internal R&D, licensing transactions, and targeted acquisitions.